People: Poxel SA (POXEL.PA)
16 Sep 2019
Dr. Thierry Hercend has served as Director of Poxel S.A. since April 18, 2016. He is Chairman of Scientific Committee. He served as Chairman of the Board of the Company until April 18, 2016. He has over 30 years of both academic and pharmaceutical experience in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Dr. Hercend has been Venture Partner at Andera Partners. From 2002 until 2005, Dr. Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe, at Vertex Pharmaceuticals. Previously, Dr. Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and was in various executive R & D positions with Roussel-Uclaf. Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Immunology unit of the Gustave Roussy Cancer Institute, Villejuif, France, Director of the Inserm unit U333 dedicated to tumor Immunology and a Professor of Immunology at the Medical Faculty of Paris XI University. He has authored more than 120 publications in oncology, auto-immune diseases and transplantation. He holds a Doctorate in Philosophy degree from Universite de Paris.
|Total Annual Compensation, EUR||--|
|Restricted Stock Award, EUR||--|
|Long-Term Incentive Plans, EUR||--|
|All Other, EUR||62,000|
|Fiscal Year Total, EUR||62,000|